News & Updates

Inflammatory bowel disease tied to pancreatic cancer risk

05 Mar 2024

Patients with inflammatory bowel disease (IBD) appear to have a moderately elevated risk of pancreatic cancer, according to a meta-analysis.

Inflammatory bowel disease tied to pancreatic cancer risk

05 Mar 2024

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024 by

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024 by

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Nonpreventable readmission prevalent in patients with cirrhosis

04 Mar 2024

Readmissions within 30 days are common among patients with cirrhosis, but most of these are not preventable, reveals a study.

Nonpreventable readmission prevalent in patients with cirrhosis

04 Mar 2024

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC

01 Mar 2024 by

First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC

01 Mar 2024

Pembrolizumab plus lenvatinib effective against nonclear cell RCC

29 Feb 2024 by

Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.

Pembrolizumab plus lenvatinib effective against nonclear cell RCC

29 Feb 2024

Long-term PPI use linked to higher NAFLD risk

27 Feb 2024

Taking proton pump inhibitors for a long period of time appears to increase the risk of nonalcoholic fatty liver disease (NAFLD), particularly severe hepatic steatosis, reveals a US study.